What is Zacks Research’s Forecast for Qiagen Q1 Earnings?

Qiagen N.V. (NYSE:QGEN) – Analysts at Zacks Research lowered their Q1 2026 earnings per share (EPS) estimates for shares of Qiagen in a note issued to investors on Wednesday, February 25th. Zacks Research analyst Team now expects that the company will post earnings of $0.56 per share for the quarter, down from their prior estimate of $0.61. The consensus estimate for Qiagen’s current full-year earnings is $2.26 per share. Zacks Research also issued estimates for Qiagen’s Q2 2026 earnings at $0.63 EPS, Q3 2026 earnings at $0.65 EPS, FY2026 earnings at $2.51 EPS, Q2 2027 earnings at $0.68 EPS, Q3 2027 earnings at $0.69 EPS, FY2027 earnings at $2.81 EPS and FY2028 earnings at $3.02 EPS.

A number of other equities research analysts have also weighed in on the stock. TD Cowen reiterated a “hold” rating on shares of Qiagen in a research note on Friday, February 6th. Barclays set a $58.00 price objective on Qiagen and gave the stock an “overweight” rating in a report on Friday, February 6th. Weiss Ratings reissued a “hold (c)” rating on shares of Qiagen in a report on Monday, December 29th. Jefferies Financial Group restated a “buy” rating and set a $59.00 price target on shares of Qiagen in a research note on Thursday, February 5th. Finally, Stifel Nicolaus set a $50.00 price target on shares of Qiagen and gave the company a “hold” rating in a research report on Friday, February 6th. Four equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, Qiagen currently has an average rating of “Hold” and an average target price of $55.20.

Qiagen Stock Up 1.5%

Shares of Qiagen stock opened at $49.81 on Friday. Qiagen has a twelve month low of $39.61 and a twelve month high of $57.81. The company has a quick ratio of 3.31, a current ratio of 3.90 and a debt-to-equity ratio of 0.44. The company’s 50 day moving average is $50.01 and its 200 day moving average is $49.37. The company has a market cap of $10.52 billion, a price-to-earnings ratio of 24.71, a price-to-earnings-growth ratio of 2.39 and a beta of 0.67.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Thursday, February 5th. The company reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.61 by $0.01. Qiagen had a net margin of 20.33% and a return on equity of 14.56%. The firm had revenue of $540.42 million for the quarter, compared to the consensus estimate of $528.53 million. During the same quarter last year, the firm posted $0.61 EPS. The business’s quarterly revenue was up 3.6% compared to the same quarter last year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of QGEN. Lingohr Asset Management GmbH purchased a new stake in shares of Qiagen during the third quarter worth about $4,218,000. Gateway Investment Advisers LLC purchased a new position in Qiagen in the 3rd quarter worth approximately $1,197,000. SG Americas Securities LLC bought a new position in Qiagen in the 3rd quarter worth approximately $1,032,000. Great Lakes Advisors LLC purchased a new stake in Qiagen during the 3rd quarter valued at approximately $3,677,000. Finally, Generali Asset Management SPA SGR raised its position in shares of Qiagen by 102.8% during the third quarter. Generali Asset Management SPA SGR now owns 68,880 shares of the company’s stock valued at $3,078,000 after buying an additional 34,912 shares during the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

More Qiagen News

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: DWS Investment disclosed a 2.76% voting stake in Qiagen — a notable institutional position that can lend support to the share price, raise confidence among other investors and prompt speculation about engagement or strategic influence. DWS Investment Discloses 2.76% Voting Stake in Qiagen
• Positive Sentiment: Reports show large volumes of Qiagen call options were purchased, indicating bullish positioning or short-term speculative interest that can amplify upward moves in the stock and attract momentum traders. Investors Buy Large Volume of Qiagen Call Options (NYSE:QGEN)
• Negative Sentiment: Zacks Research reduced EPS estimates across multiple near-term quarters and trimmed FY2026 and FY2027 forecasts (FY2026 cut from $2.57 to $2.51; FY2027 trimmed to $2.81 from $2.85), and lowered several quarterly estimates (Q1–Q3 2026 and Q2–Q3 2027). Those downgrades signal weaker near-term earnings growth expectations and could limit upside if revisions continue.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.